Cleave Therapeutics
Series C in 2019
Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.
Exosome Diagnostics
Series C in 2017
Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.
Cleave Therapeutics
Series B in 2016
Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.
Exosome Diagnostics
Series B in 2016
Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.
Exosome Diagnostics
Series B in 2015
Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.
XTuit Pharmaceuticals
Series A in 2015
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics that target the disease-promoting microenvironment associated with fibrotic diseases and cancer. Established in 2011 and based in Waltham, Massachusetts, the company is engaged in creating pharmaceutical preparations aimed at diagnosing and treating oncological, tumor, and inflammatory diseases. XTuit Pharmaceuticals employs novel strategies to enhance cancer therapy by specifically addressing the tumor microenvironment. Its drug development pipeline includes innovative approaches that inhibit extracellular matrix synthesis and stabilize activated stromal cells, utilizing a clinical biomarker platform for effective treatment outcomes.
TRACON Pharmaceuticals
Series B in 2014
TRACON Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development and commercialization of targeted therapies for cancer and wet age-related macular degeneration (AMD). Its lead product, envafolimab, is a PD-L1 single-domain antibody under investigation for soft tissue sarcoma, while other clinical candidates include TRC102, a small molecule in Phase II trials for lung cancer, and TJ004309, a CD73 antibody in Phase I development for advanced solid tumors. TRACON's development pipeline also features TRC253, which is being studied for metastatic castration-resistant prostate cancer. The company employs a capital-efficient, CRO-independent product development platform and actively seeks partnerships with companies outside the U.S. for regulatory and clinical development, as well as commercialization in the U.S. TRACON was founded in 2004 and was previously known as Lexington Pharmaceuticals until its rebranding in 2005.
Epic Sciences
Series C in 2014
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.
Exosome Diagnostics
Series B in 2014
Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.
MI Bioresearch
Series B in 2013
MI Bioresearch is a specialty contract research organization (CRO) providing in vivo preclinical imaging services. With a proven track record of imaging and drug discovery expertise, the company enhances preclinical and translational research through its in vivo pharmaco-IMAGING platform. This combination of traditional pharmacology and innovative imaging includes MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and fluorescence molecular tomography) tools to quantitatively measure the response to therapy at anatomical, functional and molecular levels. Molecular Imaging also provides supportive in vitro services. They have performed over 2000 cell line based traditional oncology studies and over 500 imaging enhanced studies since their founding in 2003.
T2 Biosystems
Series E in 2013
T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.
MI Bioresearch
Series A in 2012
MI Bioresearch is a specialty contract research organization (CRO) providing in vivo preclinical imaging services. With a proven track record of imaging and drug discovery expertise, the company enhances preclinical and translational research through its in vivo pharmaco-IMAGING platform. This combination of traditional pharmacology and innovative imaging includes MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and fluorescence molecular tomography) tools to quantitatively measure the response to therapy at anatomical, functional and molecular levels. Molecular Imaging also provides supportive in vitro services. They have performed over 2000 cell line based traditional oncology studies and over 500 imaging enhanced studies since their founding in 2003.
Oncoscope
Seed Round in 2011
Oncoscope, Inc. is a medical device company based in Durham, North Carolina, established in 2006. The company specializes in developing optical imaging systems that focus on epithelial tissues located in various parts of the body, including the oral cavity, esophagus, stomach, colon, lung, cervix, and bladder. Its innovative systems deliver in vivo measurements that provide critical information on tissue microstructure, specifically assessing the diameter and density of cell nuclei. This technology aims to improve clinical outcomes by offering detailed insights into the health of epithelial tissues.
T2 Biosystems
Series D in 2011
T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.
MI Bioresearch
Series A in 2011
MI Bioresearch is a specialty contract research organization (CRO) providing in vivo preclinical imaging services. With a proven track record of imaging and drug discovery expertise, the company enhances preclinical and translational research through its in vivo pharmaco-IMAGING platform. This combination of traditional pharmacology and innovative imaging includes MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and fluorescence molecular tomography) tools to quantitatively measure the response to therapy at anatomical, functional and molecular levels. Molecular Imaging also provides supportive in vitro services. They have performed over 2000 cell line based traditional oncology studies and over 500 imaging enhanced studies since their founding in 2003.
TRACON Pharmaceuticals
Series A in 2011
TRACON Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development and commercialization of targeted therapies for cancer and wet age-related macular degeneration (AMD). Its lead product, envafolimab, is a PD-L1 single-domain antibody under investigation for soft tissue sarcoma, while other clinical candidates include TRC102, a small molecule in Phase II trials for lung cancer, and TJ004309, a CD73 antibody in Phase I development for advanced solid tumors. TRACON's development pipeline also features TRC253, which is being studied for metastatic castration-resistant prostate cancer. The company employs a capital-efficient, CRO-independent product development platform and actively seeks partnerships with companies outside the U.S. for regulatory and clinical development, as well as commercialization in the U.S. TRACON was founded in 2004 and was previously known as Lexington Pharmaceuticals until its rebranding in 2005.
Vascular Pathways
Series B in 2010
Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of its flagship product, the Rapid IntraVascular Start (RIVS) catheter. This FDA-cleared device is designed to facilitate rapid, safe, and successful peripheral intravenous (IV) insertion, addressing a critical need in medical settings. By streamlining the process of IV placement, Vascular Pathways aims to enhance patient care and improve outcomes in various healthcare environments.
Clear Vascular
Venture Round in 2010
Clear Vascular, Inc. is a clinical-stage company focused on developing innovative pharmaceutical products for the treatment of cardiovascular diseases. Founded in 2005 by Dr. Gilbert Gonzales, the company specializes in imaging and therapeutically addressing vulnerable plaque and other vascular inflammatory conditions. Their primary product, Tin-Annexin, utilizes tin-117m, a radioisotope developed in collaboration with the US Department of Energy and Brookhaven National Laboratory. This product has undergone various pre-clinical and clinical trials, demonstrating its effectiveness in both imaging and treating inflammatory tissues associated with unstable plaque. The production of tin-117m has evolved through advanced methods, including a proton accelerator and an innovative technique developed by Dr. Nigel Stevenson, which employs alpha particles and cadmium-116 as a target material. This allows for scalable manufacturing of the product, enhancing the potential for timely treatment for patients suffering from cardiovascular issues.
T2 Biosystems
Series C in 2010
T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.
Oncoscope
Venture Round in 2010
Oncoscope, Inc. is a medical device company based in Durham, North Carolina, established in 2006. The company specializes in developing optical imaging systems that focus on epithelial tissues located in various parts of the body, including the oral cavity, esophagus, stomach, colon, lung, cervix, and bladder. Its innovative systems deliver in vivo measurements that provide critical information on tissue microstructure, specifically assessing the diameter and density of cell nuclei. This technology aims to improve clinical outcomes by offering detailed insights into the health of epithelial tissues.
Palyon Medical
Series A in 2009
Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.
MacroGenics
Series D in 2008
MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the discovery and development of antibody-based therapeutics for cancer treatment. Founded in 2000, the company focuses on immuno-oncology and has a diverse pipeline of product candidates. Key developments include Margetuximab, a monoclonal antibody in Phase III clinical trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include MGA012, MGD013, MGD019, and Enoblituzumab, which target various immune checkpoints and tumor-associated antigens. MacroGenics is also advancing combination therapies and antibody-drug conjugates, such as MGC018, which targets solid tumors expressing B7-H3. The company has formed strategic collaborations with notable partners, enhancing its research and development efforts in the biopharmaceutical landscape.
Genta
Venture Round in 1991
Genta Incorporated is a biopharmaceutical company that specializes in the development and commercialization of cancer treatment drugs. With a focus on identifying and advancing innovative therapies, Genta has established a diverse portfolio of proprietary products at different stages of clinical development. Some of the key drugs in the Company's pipeline include Ganite (gallium nitrate injection), tesetaxel, and oral gallium. By leveraging its expertise in oncology research and drug development, Genta aims to address the unmet medical needs of cancer patients and improve outcomes in the field of oncology.